Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience

Myelodysplastic syndromes (MDS) encompass a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production, leading to significant cytopenia and a variable risk of transformation to acute myelogenous leukemia (AML) [1].

Source: Biology of Blood and Marrow Transplantation - February 20, 2018 Category: Hematology Authors: Musa Alzahrani, Maryse Power, Yasser Abou Mourad, Michael Barnett, Raewyn Broady, Donna Forrest, Alina Gerrie, Donna Hogge, Stephen Nantel, David Sanford, Kevin Song, Heather Sutherland, Cynthia Toze, Thomas Nevill, Sujaatha Narayanan Source Type: research